GE HealthCare slip after $945 million deal for Sofie Biosciences

** Shares of medical device maker GE HealthCare GEHC.O fall more than 1% to $63.55

** Co says it would buy privately held Sofie Biosciences for $945 million in cash

** Acquisition to give co US rights to FAPI-74, an experimental PET imaging agent in late-stage testing that could be used to detect several types of cancer

** Co already owns rights to the product outside the US

** Says Sofie would continue to manufacture products for existing customers, including other radiopharma companies, after the transaction closes, which is expected in the first half of 2027

** 15 of 21 brokerages rate stock "buy" or above, 6 "hold"; median PT - $85 - data compiled by LSEG

** Including session's moves, stock has fallen 22.5% YTD